Last reviewed · How we verify

Beta-lactam antibiotic — Competitive Intelligence Brief

Beta-lactam antibiotic (Beta-lactam antibiotic) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-lactam antibiotic. Area: Infectious Disease.

marketed Beta-lactam antibiotic Penicillin-binding proteins (PBPs); bacterial cell wall peptidoglycan Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Beta-lactam antibiotic (Beta-lactam antibiotic) — University Hospital, Ghent. Beta-lactam antibiotics inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins and blocking peptidoglycan cross-linking.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Beta-lactam antibiotic TARGET Beta-lactam antibiotic University Hospital, Ghent marketed Beta-lactam antibiotic Penicillin-binding proteins (PBPs); bacterial cell wall peptidoglycan
Amoxil amoxicillin Generic (originally Beecham/GSK) marketed Aminopenicillin (Beta-lactam antibiotic) 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C 1972-01-01
Bicillin C-R Penicillin G Benzathine Pfizer marketed Beta-lactam antibiotic Cell-wall peptidoglycan biosynthesis 1952-01-01
Bicillin C-R Penicillin G Benzathine Pfizer marketed Beta-lactam antibiotic Cell-wall peptidoglycan biosynthesis 1952-01-01
high dose amoxicillin/clavulanate high dose amoxicillin/clavulanate Albany Medical College marketed Beta-lactam antibiotic with beta-lactamase inhibitor Penicillin-binding proteins (PBPs); beta-lactamase
ampicillin/clavulanate ampicillin/clavulanate Phoenix Children's Hospital marketed Beta-lactam antibiotic with beta-lactamase inhibitor Penicillin-binding proteins (PBPs); bacterial beta-lactamases
Third generation cephalosporins Third generation cephalosporins Wyeth is now a wholly owned subsidiary of Pfizer marketed Beta-lactam antibiotic (cephalosporin) Penicillin-binding proteins (PBPs)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (Beta-lactam antibiotic class)

  1. Pfizer · 2 drugs in this class
  2. Bayer · 1 drug in this class
  3. Belén Retamal-Valdes · 1 drug in this class
  4. Benova (Tianjin) Innovative medicine Research Co., Ltd. · 1 drug in this class
  5. Esraa Salah Mohamed Abdallah Eladl · 1 drug in this class
  6. Incheon St.Mary's Hospital · 1 drug in this class
  7. International Maternal Pediatric Adolescent AIDS Clinical Trials Group · 1 drug in this class
  8. KEMRI-Wellcome Trust Collaborative Research Program · 1 drug in this class
  9. National Taiwan University Hospital · 1 drug in this class
  10. Pfizer Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Beta-lactam antibiotic — Competitive Intelligence Brief. https://druglandscape.com/ci/beta-lactam-antibiotic. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: